BioPharmSignal logoBioPharmSignal

Biotech News

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

Adaptive Biotechnologies (ADPT)Adaptive BiotechnologiesEarnings

SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial

Related news

ADPTAdaptive Biotechnologies2026-07-09 20:05 EST

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

ANGOAngioDynamics2026-06-30 12:00 EST

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

ANGOAngioDynamics2026-07-14 10:00 EST

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

XAIRBeyond Air2026-06-26 11:00 EST

Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

ACHCAcadia Healthcare2026-07-28 20:05 EST

Acadia Healthcare Announces Second Quarter 2026 Results and Updates Full Year 2026 Financial and Cash Flow Guidance

STIMNeuronetics2026-07-28 12:30 EST

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

CVRXCVRx2026-07-23 20:30 EST

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

FEMYFEMASYS2026-08-14 20:05 EST

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

View all latest news

Adaptive Biotechnologies

Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics. Minimal Residual Disease The...

Recent company news

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

ADPTAdaptive Biotechnologies2026-07-09 20:05 EST

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

ADPTAdaptive Biotechnologies2026-06-30 12:30 EST

Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

ADPTAdaptive Biotechnologies2026-06-17 10:00 EST

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-15 20:10 EST

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

Stock data

Close
25.99 USD
Market cap
2.42B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States